Ironwood Pharmaceuticals
IRWD
158 hedge funds and large institutions have $2.29B invested in Ironwood Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 51 increasing their positions, 49 reducing their positions, and 18 closing their positions.
100% more call options, than puts
Call options by funds: $17.8M | Put options by funds: $8.92M
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
6% more funds holding
Funds holding: 149 → 158 (+9)
4% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 49
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4.16% less ownership
Funds ownership: 138.95% → 134.79% (-4.2%)
8% less capital invested
Capital invested by funds: $2.48B → $2.29B (-$188M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$25.7M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$14.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.1M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$9.57M |
| 5 |
JP Morgan Chase
New York
|
+$6.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$44.5M |
| 2 |
BM
Bridger Management
New York
|
-$40.2M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$21.8M |
| 4 |
O
OrbiMed
New York
|
-$19.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.8M |
IRWD Hedge Fund Activity: Q4 2017 in Review
158 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2017, worth a combined $2.29B — down 7.6% from $2.48B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new IRWD positions and 18 closed out — a net gain of 9 holders — while 51 added to existing stakes and 49 trimmed.
The largest buyer was Sarissa Capital Management, opening a new position worth an estimated $25.7M. The largest seller was BVF Inc, exiting entirely with an estimated $44.5M sold.
- 158 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2017, up from 149 in Q3 2017.
- Funds reported $2.29B of Ironwood Pharmaceuticals stock for Q4 2017, down 7.6% quarter-over-quarter.
- 27 funds opened new Ironwood Pharmaceuticals positions in Q4 2017 and 18 closed out, a net change of +9 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2017 was Sarissa Capital Management, an estimated $25.7M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2017 was BVF Inc, an estimated $44.5M sold.
Based on aggregated 13F filings for Q4 2017.